Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Yekaterina Anokhina"'
Autor:
Anna Semenova, Irina Baldueva, Svetlana Protsenko, Yekaterina Anokhina, Aleksey Novik, A. Oganesian
Publikováno v:
Problems in oncology. 66:211-217
Immune checkpoint inhibitors are the most promising treatment option for many histological subtypes of malignant tumors, providing a long objective response and an increase in overall survival. Currently, there is growing evidence of the specific het
Autor:
Irina Baldueva, Svetlana Protsenko, Gulfiya Midhatovna Teletaeva, Yekaterina Yaremenko, Aleksey Novik, Dilorom Latipova, Tatyana Semiglazova, V. Rubinchik, Anna Semenova, Yekaterina Anokhina, Ani Oganesyan
Publikováno v:
Problems in oncology. 64:388-393
Ipilimumab (IPI) provides a ten-year overall survival in almost 20 % of selected patients participated in several phase II-III trials. However, the expanded access program (EAP) looks more like routine practice than like clinical trials& This is why
Autor:
Gulfiya Midhatovna Teletaeva, Filatova Lv, Dilorom Latipova, Veronika Klimenko, Irina Baldueva, Mikhail Osipov, Yuriy Komarov, Z. S. Kotova, Natalya Buevich, Anna Semenova, Margarita Motalkina, Aleksandr Stukov, Svetlana Protsenko, Yekaterina Anokhina, Tatyana Semiglazova, Yevgeniya Kharchenko, Aleksey Novik, Sergey Alekseev
Publikováno v:
Problems in oncology. 63:346-352
In 1947 for the first time in the USSR in the Leningrad Institute of Oncology L.F. Larionov and and V.G. Nemets have developed and clinically tested the first domestic cytostatic embihin. Since that time more than 150 different anti-cancer agents and
Autor:
Anna Semenova, N. Avdokina, Anna Danilova, Yuriy Komarov, Natalya Yemelyanova, Aleksey Belyaev, Mark Gelfond, Aleksey Novik, Irina Baldueva, Aleksandr Shcherbakov, Tatyana Nekhaeva, Olga Galiullina, Nino Pipia, Yekaterina Anokhina, Dilorom Latipova, Svetlana Protsenko, Tatyana Semiglazova, Gulfiya Midhatovna Teletaeva, Z. S. Kotova
Publikováno v:
Problems in oncology. 63:336-345
There are described the results of clinical and immunological efficacy assessment of active specific immunotherapy with autologous immature dendritic cells (DC) combined with photodynamic therapy (PDT) and cyclophosphamide (C) in disseminated melanom